metabolic works, page-6

"...it will be very expensive to trial and bring to market, according to Metabolic."

No doubt. But how much more expensive is it to trial a drug and then NOT take it to market.

The key thing is that they need to prove just ONE drug and get the thing licensed to someone, or find a customer for an injected/oral peptide conversion. Anything that generates actual INCOME to the company.

With actual income from operations, the company will prove its credibility, the stock price will stabilize and rise, multiple drug trials can be funded out of earnings avoiding the constant dilution of equity, and really, all things become possible.

But, first things first. The next best main chance is ACV1, and with positive results in June (or whenever) the share price could move back up to the levels of the past couple years, i.e. 40 to 45 cents. With a licensing deal we'd be back above $1.00 fairly quickly.

Then, with solid science to back up the decision, human trials to bring AOD9604 to market as an osteoporosis drug won't seem like such a hurdle.

And, as I have noted, once the drug is available to physicians to prescribe, you can bet that they will be prescribing it for weight loss. This is as certain as the sunrise.

The company will need to find some way to extend the patent protection, though. At the rate they are going the drug will be a generic by the time they get it to market.